Alligator Bioscience to present new preclinical data on ATOR-1015 at PEGS Boston
Tumor-localizing properties of bispecific antibody demonstrated by live imaging Lund, Sweden, April 10, 2019 – Alligator Bioscience (Nasdaq ...
Alligator Bioscience: New preclinical data for ATOR-1144 demonstrate potential for activation of both the innate and the adaptive immune system, as well as direct anti-tumor effects
Lund, Sweden, April 2, 2019 – Alligator Bioscience (Nasdaq Stockholm: ATORX), today announce that new preclinical data on the drug candidate ...
Alligator Bioscience’s Annual Report 2018 published
Lund, Sweden, 22 March 2019 – Alligator Bioscience (Nasdaq Stockholm: ATORX), a biotechnology company developing antibody-based pharmaceutic ...
Alligator Bioscience: New preclinical data demonstrate strong anti-tumor effects for the 4-1BB antibody ATOR-1017
Lund, Sweden, March 18, 2019 – Alligator Bioscience (Nasdaq Stockholm: ATORX), today announce that they will present preclinical data for th ...
Alligator Bioscience: First Patient Dosed in Phase I study of ATOR-1015
Dose-escalation study commences with first-in-class bispecific CTLA-4 antibody Lund, Sweden, March 7, 2019 – Alligator Bioscience (Nasdaq St ...
Alligator Bioscience AB Year-end Report 2018
The bispecific drug candidate ATOR-1015 in clinical development Significant events October-December• The Swedish MPA (Medical Products Agenc ...
Alligator Bioscience to Host Conference Call to Provide Year-end Report 2018 Business Update
Alligator Bioscience (Nasdaq Stockholm: ATORX) – On 14 February 2019, at 08:00 a.m. CET, Alligator Bioscience will publish its report ...
Alligator Bioscience publishes clinical phase I data for ADC-1013 in the International Journal of Cancer
First-in-human study with intratumoral administration of a CD40 agonistic antibody, ADC-1013, in advanced solid malignancies Lund, Sweden, J ...
Alligator Bioscience launches RUBY™, a novel concept in bispecific antibody formats
Priority filling submitted RUBY™ bispecific concept has been developed to achieve an outstanding stability, manufacturability and shorter de ...